BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 17420404)

  • 1. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
    Rabinovici GD; Furst AJ; O'Neil JP; Racine CA; Mormino EC; Baker SL; Chetty S; Patel P; Pagliaro TA; Klunk WE; Mathis CA; Rosen HJ; Miller BL; Jagust WJ
    Neurology; 2007 Apr; 68(15):1205-12. PubMed ID: 17420404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients.
    Rostomian AH; Madison C; Rabinovici GD; Jagust WJ
    J Nucl Med; 2011 Feb; 52(2):173-9. PubMed ID: 21233181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Accuracy of Amyloid versus
    Lesman-Segev OH; La Joie R; Iaccarino L; Lobach I; Rosen HJ; Seo SW; Janabi M; Baker SL; Edwards L; Pham J; Olichney J; Boxer A; Huang E; Gorno-Tempini M; DeCarli C; Hepker M; Hwang JL; Miller BL; Spina S; Grinberg LT; Seeley WW; Jagust WJ; Rabinovici GD
    Ann Neurol; 2021 Feb; 89(2):389-401. PubMed ID: 33219525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.
    Rabinovici GD; Rosen HJ; Alkalay A; Kornak J; Furst AJ; Agarwal N; Mormino EC; O'Neil JP; Janabi M; Karydas A; Growdon ME; Jang JY; Huang EJ; Dearmond SJ; Trojanowski JQ; Grinberg LT; Gorno-Tempini ML; Seeley WW; Miller BL; Jagust WJ
    Neurology; 2011 Dec; 77(23):2034-42. PubMed ID: 22131541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
    Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
    Rowe CC; Ackerman U; Browne W; Mulligan R; Pike KL; O'Keefe G; Tochon-Danguy H; Chan G; Berlangieri SU; Jones G; Dickinson-Rowe KL; Kung HP; Zhang W; Kung MP; Skovronsky D; Dyrks T; Holl G; Krause S; Friebe M; Lehman L; Lindemann S; Dinkelborg LM; Masters CL; Villemagne VL
    Lancet Neurol; 2008 Feb; 7(2):129-35. PubMed ID: 18191617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
    Womack KB; Diaz-Arrastia R; Aizenstein HJ; Arnold SE; Barbas NR; Boeve BF; Clark CM; DeCarli CS; Jagust WJ; Leverenz JB; Peskind ER; Turner RS; Zamrini EY; Heidebrink JL; Burke JR; DeKosky ST; Farlow MR; Gabel MJ; Higdon R; Kawas CH; Koeppe RA; Lipton AM; Foster NL
    Arch Neurol; 2011 Mar; 68(3):329-37. PubMed ID: 21059987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
    Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
    Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
    Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
    Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
    J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.